-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] According to the statistics of Oriental Fortu.
com's institutional survey data, from July 1 to now (July 27), 815 listed companies have received institutional surve.
From the perspective of the industries to which the surveyed companies belong, they are mainly concentrated in pharmaceutical biolo.
, machinery and equipment, electronics, communications, computers and other industri.
It can be seen that the pharmaceutical and biological industry is still the key area of institutional resear.
11 companies have obtained more than 20 institutions for research In the pharmaceutical and biological industry, according to the author's incomplete statistics, at least 11 companies have received research from more than 20 institutions, including Mingyue Lens, Kaili Medical, Huadong Medicine, Steady Medical, Livzon Group e.
_In the institutional survey list, Mingyue Lens has attracted a lot of attention, with 147 institutions participating in the survey, followed by Huadong Medicine and Kaili Medical, with more than 100 reception institutions, 140 and 124 respective.
Judging from the number of institutional surveys, Huakang medical institutions have relatively intensive surveys, with a total of 4 surveys from institutio.
Aier Ophthalmology has also received attention from institutions for many times, and the number of institutional investigations has reached 3 tim.
Rhein Bio, Kaili Medical, and Huadong Medicine have received 2 investigations by institutions, while most other pharmaceutical companies have conducted 1 investigatio.
In terms of research content, the Q&A session for investors mainly focuses on the operating conditions and future plans of relevant compani.
It is worth mentioning that many pharmaceutical companies were asked about the impact of centralized procureme.
For pharmaceutical companies, the price reduction trend brought about by the normalization of centralized procurement has become an unavoidable challen.
Pharmaceutical companies that want to enter the centralized procurement need to actively respond and exchange price for quanti.
For example, Huadong Medicine said in an institutional survey that the company's main products Bailing Capsules, Acarbose Tablets, and Pantoprazole Sodium for Injection have all experienced medical insurance negotiation and price reduction by national centralized procureme.
In June this year, the company's Acarbose Tablets and Pantoprazole Sodium for Injection were successfully selected for purchase by the drug alliance of thirteen provinces (autonomous regions, municipalities, and Corps) including Henan, and will be implemented successively in Ju.
Bidding for contract renewals will also be launched in the second half of the ye.
The in-hospital market share of the above products is expected to further increase and stabili.
In addition, among the research stocks gathered by institutions, 4 individual stocks rose, and the top gainers were Huadong Medicine, Mingyue Lens, Kexing Pharmaceuticals, e.
, with increases of 82%, 77%, and 28% respectively; 6 stocks fell, the decline The top companies are Aier Ophthalmology and Kanglong Chemical, with declines of 92% and 50% respective.
5 companies have announced their semi-annual report performance foreca.
As of now, among the 11 stocks, no pharmaceutical company has disclosed their 2022 semi-annual repo.
Joy is the ma.
Among them, Kaili Medical announced on July 7 that it is expected to achieve a net profit of 160 million to 200 million yuan attributable to shareholders of listed companies in the first half of 2022, an increase of 472% to 184% over the same period last ye.
Steady Medical released its semi-annual performance forecast on the evening of July 1 It is expected that the main business income will reach 92 billion yuan to 118 billion yuan in the first half of 2022, a year-on-year increase of 22% to 12
RheinBio released a performance forecast on the evening of June 2 It is expected that the net profit attributable to shareholders of listed companies in the first half of 2022 will be about 119 million to 149 million yuan, a year-on-year increase of 100% to 15
Kanglong Chemical released the 2022 semi-annual report performance forecast on July 1 It is expected that the operating income will be 567 billion to 1665 billion yuan, and the net profit attributable to shareholders of the listed company will be 565 million to 610 million yuan, a year-on-year increase of 00% to 10Meinian Health released its 2022 semi-annual performance forecast on the evening of July 1The forecast shows that Meinian Health expects operating income of 85 billion yuan to 13 billion yuan in the first half of this year, and a net profit loss of 630 million yuan to 680 million yuan attributable to shareholders of listed compani.
List of research stocks from over 20 institutions since July Note: The picture comes from the pharmaceutical network, and the data comes from the Oriental Fortune Network
com's institutional survey data, from July 1 to now (July 27), 815 listed companies have received institutional surve.
From the perspective of the industries to which the surveyed companies belong, they are mainly concentrated in pharmaceutical biolo.
, machinery and equipment, electronics, communications, computers and other industri.
It can be seen that the pharmaceutical and biological industry is still the key area of institutional resear.
11 companies have obtained more than 20 institutions for research In the pharmaceutical and biological industry, according to the author's incomplete statistics, at least 11 companies have received research from more than 20 institutions, including Mingyue Lens, Kaili Medical, Huadong Medicine, Steady Medical, Livzon Group e.
_In the institutional survey list, Mingyue Lens has attracted a lot of attention, with 147 institutions participating in the survey, followed by Huadong Medicine and Kaili Medical, with more than 100 reception institutions, 140 and 124 respective.
Judging from the number of institutional surveys, Huakang medical institutions have relatively intensive surveys, with a total of 4 surveys from institutio.
Aier Ophthalmology has also received attention from institutions for many times, and the number of institutional investigations has reached 3 tim.
Rhein Bio, Kaili Medical, and Huadong Medicine have received 2 investigations by institutions, while most other pharmaceutical companies have conducted 1 investigatio.
In terms of research content, the Q&A session for investors mainly focuses on the operating conditions and future plans of relevant compani.
It is worth mentioning that many pharmaceutical companies were asked about the impact of centralized procureme.
For pharmaceutical companies, the price reduction trend brought about by the normalization of centralized procurement has become an unavoidable challen.
Pharmaceutical companies that want to enter the centralized procurement need to actively respond and exchange price for quanti.
For example, Huadong Medicine said in an institutional survey that the company's main products Bailing Capsules, Acarbose Tablets, and Pantoprazole Sodium for Injection have all experienced medical insurance negotiation and price reduction by national centralized procureme.
In June this year, the company's Acarbose Tablets and Pantoprazole Sodium for Injection were successfully selected for purchase by the drug alliance of thirteen provinces (autonomous regions, municipalities, and Corps) including Henan, and will be implemented successively in Ju.
Bidding for contract renewals will also be launched in the second half of the ye.
The in-hospital market share of the above products is expected to further increase and stabili.
In addition, among the research stocks gathered by institutions, 4 individual stocks rose, and the top gainers were Huadong Medicine, Mingyue Lens, Kexing Pharmaceuticals, e.
, with increases of 82%, 77%, and 28% respectively; 6 stocks fell, the decline The top companies are Aier Ophthalmology and Kanglong Chemical, with declines of 92% and 50% respective.
5 companies have announced their semi-annual report performance foreca.
As of now, among the 11 stocks, no pharmaceutical company has disclosed their 2022 semi-annual repo.
Joy is the ma.
Among them, Kaili Medical announced on July 7 that it is expected to achieve a net profit of 160 million to 200 million yuan attributable to shareholders of listed companies in the first half of 2022, an increase of 472% to 184% over the same period last ye.
Steady Medical released its semi-annual performance forecast on the evening of July 1 It is expected that the main business income will reach 92 billion yuan to 118 billion yuan in the first half of 2022, a year-on-year increase of 22% to 12
RheinBio released a performance forecast on the evening of June 2 It is expected that the net profit attributable to shareholders of listed companies in the first half of 2022 will be about 119 million to 149 million yuan, a year-on-year increase of 100% to 15
Kanglong Chemical released the 2022 semi-annual report performance forecast on July 1 It is expected that the operating income will be 567 billion to 1665 billion yuan, and the net profit attributable to shareholders of the listed company will be 565 million to 610 million yuan, a year-on-year increase of 00% to 10Meinian Health released its 2022 semi-annual performance forecast on the evening of July 1The forecast shows that Meinian Health expects operating income of 85 billion yuan to 13 billion yuan in the first half of this year, and a net profit loss of 630 million yuan to 680 million yuan attributable to shareholders of listed compani.
List of research stocks from over 20 institutions since July Note: The picture comes from the pharmaceutical network, and the data comes from the Oriental Fortune Network
